Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure

Henry D. Jampel, Jason Bacharach, Wang Pui Sheu, Lisa G. Wohl, Alfred M. Solish, William Christie

Research output: Contribution to journalArticlepeer-review

Abstract

PURPOSE: To compare the intraocular pressure (IOP)-lowering effect and safety of latanoprost 0.005% once daily with that of unoprostone 0.15% twice daily for patients with primary open-angle glaucoma or ocular hypertension. DESIGN: Randomized clinical trial. METHODS: In a prospective, 8-week, investigator-masked, parallel-group study conducted at numerous centers in the United States, 165 previously treated patients with IOP ≥ 25 mm Hg in one or both eyes after washout were randomly assigned to receive either latanoprost 0.005% once daily in the evening or unoprostone 0.15% twice daily. Observations procedures were Goldmann applanation tonometry, best-corrected visual acuity, slit lamp biomicroscopy, and ophthalmoscopy. The main outcome measure was change in the mean of the IOPs measured at 8:00 AM, 12 noon, and 4:00 PM between baseline (before treatment) and after 8 weeks of treatment. RESULTS: The change in the mean ± SD of the IOPs measured at 8:00 AM, 12 noon, and 4:00 PM was -7.2 ± 3.2 mm Hg (28%) for latanoprost (25.3 ± 2.8 mm Hg at baseline to 18.2 ± 2.8 mm Hg at 8 weeks) and -3.9 ± 2.6 mm Hg (15%) for unoprostone (25.5 ± 3.3 mm Hg at baseline to 21.6 ± 4.0 mm Hg; P ≤ .001. No serious adverse event related to either medication was reported. CONCLUSIONS: Over an 8-week period, latanoprost 0.005% once daily lowered IOP more than unoprostone 0.15% twice daily in patients with elevated IOP. Both agents were safe and well tolerated.

Original languageEnglish (US)
Pages (from-to)863-871
Number of pages9
JournalAmerican journal of ophthalmology
Volume134
Issue number6
DOIs
StatePublished - Dec 1 2002

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure'. Together they form a unique fingerprint.

Cite this